Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128615 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
A Phase 1 study of Influenza a, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 405
- Enrollment target
- 14
- Study locations
NCT07128615 is a Phase 1 study of Influenza a that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 405 participants, below the 2,714-participant average among 10 other Influenza a trials with a reported enrollment target (85% lower). The trial reports 14 study locations across 13 states.
The verdict
NCT07128615, a Phase 1 study of Influenza a, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 405 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL AZD4117
- BIOLOGICAL AZD5315
Study Locations (14)
California
- Research Site - Long Beach
- Research Site - Rolling Hills Estates
Florida
- Research Site - Hialeah
Georgia
- Research Site - Stockbridge
Illinois
- Research Site - Chicago
Kansas
- Research Site - Lenexa
Missouri
- Research Site - Kansas City
Nebraska
- Research Site - Omaha
Nevada
- Research Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2025-09-04 |
| Est. Completion | 2026-12-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07128615
The ClinicalTrials.gov registry entry for NCT07128615 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,714-participant average among 10 other Influenza a trials with a reported enrollment target (85% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza a appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07128615 reports 14 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07128615 about?
NCT07128615 is a clinical study titled "A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)". The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
What is the current status of trial NCT07128615?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 405 participants. The study started on 2025-09-04. Estimated completion is 2026-12-29.
What conditions does trial NCT07128615 study?
This clinical trial studies the following conditions: Influenza a.
What interventions are being tested in trial NCT07128615?
The interventions under investigation include: Placebo (OTHER), AZD4117 (BIOLOGICAL), AZD5315 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07128615?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128615 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza a
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
COMPLETED · Phase 1
-
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
COMPLETED · Phase 1
-
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients
RECRUITING · NA
-
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
COMPLETED
-
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
COMPLETED · Phase 3
-
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.